Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
04 Outubro 2022 - 8:30AM
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in
developing novel, controllable cellular immunotherapies for
cancers, today announced that Rick Fair, President and CEO, will
present at the annual Cell & Gene Meeting on the Mesa to be
held October 11-13 in Carlsbad, CA and livestreamed globally.
Details regarding Bellicum’s presentation at the conference are
as follows:
Event: 2022 Cell & Gene Meeting on the Mesa
Date: October 11, 2022Time: 4:30
p.m. PT Location: Park Hyatt Aviara Resort, 7100
Aviara Resort Dr., Carlsbad, CA 92011
Virtual attendance is available which includes a livestream of
Bellicum’s presentation and the ability to view all conference
sessions on-demand. Please visit https://meetingonthemesa.com for
full information including registration.
Complimentary attendance at this event is available for
credentialed investors and members of the media only. Investors
should contact Laura Stringham at lstringham@alliancerm.org and
interested media should contact Stephen Majors at
smajors@alliancerm.org.
About the Cell & Gene Meeting on the
Mesa
Organized by the Alliance for Regenerative Medicine, the Cell
& Gene Meeting on the Mesa is a three-day conference featuring
more than 90 dedicated company presentations by leading public and
private companies, highlighting technical and clinical achievements
over the past 12 months in the areas of cell therapy, gene therapy,
gene editing, tissue engineering, and broader regenerative medicine
technologies, as well as over 100 panelists and featured
speakers.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates,
BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell
products capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found at www.bellicum.com or
follow us on Twitter or LinkedIn.
Investors:Robert H. UhlManaging DirectorICR Westwicke
858-356-5932Robert.uhl@westwicke.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024